RAF265 (CHIR-265)

Catalog No.S2161

For research use only.

RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM in cell-free assays. RAF265 (CHIR-265) induces cell cycle arrest and apoptosis. Phase 2.

RAF265 (CHIR-265) Chemical Structure

CAS No. 927880-90-8

Selleck's RAF265 (CHIR-265) has been cited by 20 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Other Raf Products

Biological Activity

Description RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM in cell-free assays. RAF265 (CHIR-265) induces cell cycle arrest and apoptosis. Phase 2.
Targets
VEGFR2 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
30 nM(EC50) 3 nM-60 nM
In vitro

RAF265 inhibits C-Raf, wild type B-Raf and mutant (V600E) B-Raf. RAF265 effectively block phosphorylation of Raf's downstream substrates MEK and ERK in cells and also kill melanoma and colorectal cancer cell lines harboring B-Raf mutations independent of PTEN mutation status. Raf kinase inhibition by RAF265 in mutant B-Raf melanoma cell lines causes cell cycle arrest and induces apoptosis, mimicking the effect of Raf RNAi in these cells. RAF265 also potently inhibits the phosphorylation of VEGFR2 and proliferation of VEGF-stimulated hMVEC. [1] In HT29 and MDAMB231 cells, RAF265 shows inhibitory activity with IC20 of 1 to 3 μM and IC50 of 5 to 10 μM, respectively. While RAF265 leads to a significant decrease in clonogenic survival in all tested cell lines, which means that RAF265 induces a dominant effect on clonogenic survival. Addition of RAF265 to RAD001 in HCT116 cells could lead to moderately decreased AKT, S6 protein, and 4EBP1 phosphorylation. [2] Raf265 markedly reduces the protein level of Bcl-2 and great inhibitory in CM- and NCI-H727 cells, while having no effect on the TRAIL susceptibility of BON1 and GOT1 cells. [3] Protein kinase D3 (PRKD3) that when knocked down could enhance cell killing by RAF265 in A2058 melanoma cells, which prevent reactivation of MAPK signaling, induce PARP cleavage, increase caspase activity, interrupt cell-cycle progression, and inhibit colony formation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-MEL-28 NXy0[GVnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGHjWmFIem:5dHigbY5pcWKrdHnvckBw\iCVSz3NSWwuOjhiY3XscJMtKEmFNUC9NE4yPM7:TT6= MoPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{[wNlMoRjJzNUe2NFI{RC:jPh?=
MALME-3M NVf6NGhzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkDNS5Jwf3SqIHnubIljcXSrb36gc4YhVUGOTVWtN20h[2WubIOsJGlEPTB;MD6xOO69VS5? NXnTPVFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O|YxOjNpPkKxOVc3ODJ|PD;hQi=>
A375M M1PxWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HmNGdzd3e2aDDpcohq[mm2aX;uJI9nKEF|N{XNJINmdGy|LDDJR|UxRTBwMUVOwG0v M1;ORVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUe2NFI{Lz5{MUW3OlAzOzxxYU6=
A375 MW\GeY5kfGmxbjDhd5NigQ>? NUjNOFNMUW6qaXLpeIlwdiCxZjDCMXJCTiCYNkCwSUBufXSjboSgbY4hcHWvYX6gRVM4PSClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44hd2ZiRWLLMEBKSzVyPUCuNFTPxE1w M1HNV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2OlgyLz5{NkO5OlY5OTxxYU6=
Malme-3M Ml[5SpVv[3Srb36gZZN{[Xl? MoTJTY5pcWKrdHnvckBw\iCELWLBSkBXPjByRTDteZRidnRiaX6gbJVu[W5iTXHscYUuO01iY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0bY9vKG:oIFXST{whUUN3ME2wMlA1|ryPLh?= M1\yU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2OlgyLz5{NkO5OlY5OTxxYU6=
WM-1799 NEXwTYhHfW6ldHnvckBie3OjeR?= NXHveHJkUW6qaXLpeIlwdiCxZjDCMXJCTiCYNkCwSUBufXSjboSgbY4hcHWvYX6gW20uOTd7OTDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRqd25ib3[gSXJMNCCLQ{WwQVAvODUQvF2u NGC0fmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5OSd-Mk[zPVY3QDF:L3G+
MALME-3M NIDzN|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2DTF3FMVNOKGOnbHzzJIhiemKxcnnu[{BDNVKDRjDWOlAxTSCvdYThcpQtKEmFNUC9NE4xPM7:TT6= NIXSdFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5OSd-Mk[zPVY3QDF:L3G+
A375 MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiaHHyZo9zcW6pIFKtVmFHKFZ4MEDFJI12fGGwdDygTWM2OD1yLkC0{txONg>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4NUc,OjZ|OU[2PFE9N2F-
WM1799 NIDxenFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M1zI[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12xO|k6KGOnbHzzJIhiemKxcnnu[{BDNVKDRjDWOlAxTSCvdYThcpQtKEmFNUC9NE4xPM7:TT6= M{DyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2OlgyLz5{NkO5OlY5OTxxYU6=
SK-MEL-28 M{fEW2Z2dmO2aX;uJIF{e2G7 NVSxfnJnUW6qaXLpeIlwdiCxZjDCMXJCTiCYNkCwSUBufXSjboSgbY4hcHWvYX6gV2suVUWOLUK4JINmdGy|IHHzd4V{e2WmIHHzJJBpd3OyaH;yfYxifGmxbjDv[kBGWktuIFnDOVA:OC5zNN88UU4> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4NUc,OjZ|OU[2PFE9N2F-
SK-MEL-28 MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M4LFRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGijcnLvdolv\yCELWLBSkBXPjByRTDteZRidnRuIFnDOVA:OC5zNt88UU4> NF3RelQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5OSd-Mk[zPVY3QDF:L3G+
A375M NHe1[HJHfW6ldHnvckBie3OjeR?= Mnm0NVAxKG2pL3vn M4L1fYZEdWmwIHnuJI1wfXOnIIjlco9oemGodHXkJJdqfGhiaIXtZY4hSTN5NV2gZ4VtdHNiYYSgNVAxKG2pL3vnMEBxdyCzMnSsJIZEdWmwPUCuOe69VS5? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4NUc,OjZ|OU[2PFE9N2F-
A375M NYrpOJltTnWwY4Tpc44h[XO|YYm= M1jhWVExOCCvZz;r[y=> M{Dh[lQ5KGi{cx?= NHL5b5lKdmirYnn0bY9vKG:oIFKtVmFHKFZ4MEDFJI12fGGwdDDpckBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKEF|N{XNJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwNU2HSzDs[ZZmdCCrbjD0eY1weiCjdDCxNFAhdWdxa3esJJBwKHF{NDDh[pRmeiB2ODDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NG\6bXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5OSd-Mk[zPVY3QDF:L3G+
A375M NUTNXYJzTnWwY4Tpc44h[XO|YYm= NG\UZ2oyODBibXevb4c> NYjSUJh6PDhiaILz M{mzb2lvcGmkaYTpc44hd2ZiQj3SRWYhXjZyMFWgcZV1[W62IHnuJI1wfXOnIIjlco9oemGodHXkJJdqfGhiaIXtZY4hSTN5NV2gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI8uVUWNIHzleoVtKGmwIIT1cY9zKGG2IEGwNEBu\y:tZzygdI8heTKmIHHmeIVzKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= Ml\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|OU[2PFEoRjJ4M{m2OlgyRC:jPh?=
A375M M3Oy[mZ2dmO2aX;uJIF{e2G7 NEfTWZk{OCC2bzCxNFAhdWdxa3e= MkjhOEBpenN? MXrJcohq[mm2aX;uJI9nKEJvUlHGJHY3ODCHIH31eIFvfCCrbjDtc5V{\SC6ZX7v[5Ji\nSnZDD3bZRpKGi3bXHuJGE{PzWPIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBxcG:|cHjvMW1GUyCuZY\lcEBqdiC2dX3vdkBifCB|MDD0c{AyODBibXevb4ctKHCxIIGy[EBu\WG|dYLl[EBi\nSncjC0JIhzeyCyb4P0MZRpcXKmIHTvd4Uh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz M3HZV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2OlgyLz5{NkO5OlY5OTxxYU6=
A375M NYXNWI1FSW62aYT1cY9zKGG|c3H5 NFi4dIwyOCC2bzCxNFAhdWdxa3e= NITDbZc{OCCmYYnz MYHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1UUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBz\We{ZYPzbY9vKGG2IEGwJJRwKDFyMDDt[{9s\yxicH:gdVJlKG2nYYP1doVlKHWyIITvJFMxKGSjeYO= NVTaS4ltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDFpPkK2N|k3PjhzPD;hQi=>
TC32 MXzxTHRUKGG|c3H5 MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? M1HTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M3j4[pFJXFNiYYPzZZk> NVfNN2c6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= NEXzdYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 M3XvZpFJXFNiYYPzZZk> NF\OTIhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> M{nqV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NWXxWJRyeUiWUzDhd5NigQ>? M4L3UpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NHvmRW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC M4jaOZFJXFNiYYPzZZk> MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= M4fUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 Mnu3dWhVWyCjc4PhfS=> M3L5U5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 MXfxTHRUKGG|c3H5 MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= M1PpXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS NXXRfZpweUiWUzDhd5NigQ>? NEPuTnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MX\xTHRUKGG|c3H5 M{HHRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= M37JO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MXXxTHRUKGG|c3H5 M3;UcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz M{fWc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MVPxTHRUKGG|c3H5 M3X4RZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NGjzOWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 M4TySZFJXFNiYYPzZZk> NYS5W|J7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NXHQWXZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NXv4RY1{eUiWUzDhd5NigQ>? M{XxXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MlHxdWhVWyCjc4PhfS=> MnrzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NXnJe2F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 M2ruT5FJXFNiYYPzZZk> NETNZZdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN? NVXJdFhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC M3vDfpFJXFNiYYPzZZk> NVvKboh2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 M1XoWZFJXFNiYYPzZZk> NIq3d|ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>? NG\3Om09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 MULxTHRUKGG|c3H5 M1vNVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN? NETHdXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 M3\jeJFJXFNiYYPzZZk> Mkm1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM> NI\XOnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NFXZPIJyUFSVIHHzd4F6 MoTGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MkXQdWhVWyCjc4PhfS=> NU\zTXNseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
VERO-E6 M2HzcWZ2dmO2aX;uJIF{e2G7 NXXJSZVOPDhiaILz NFfmWVZVd3irY3n0fUBESzVyIHHnZYlve3RiVlXSU{1GPiClZXzsd{Bl\XSncn3pcoVlKGG2IES4JIhwfXK|IHL5JIhq\2hiY3;ueIVvfCCrbXHnbY5oKCi|YX3lJINwdmSrdHnvcpMh[XNiMm;MSXkhf2m2aH;1eEBmgHCxc4Xy[UB1dyByLkCxJG1QUSCVQWLTJGNwXi1{II\pdpV{MSxiQ1O1NF06NjF7zszNMi=> NV;PZllNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV6N{WyM{c,S2iHTVLMQE9iRg>?
VERO-E6 MVfGeY5kfGmxbjDhd5NigQ>? NVi3VmZVPDhiaILz M4XtWWRmfGW{bXnuZZRqd25ib3[gTWM2OCC4YXz1[ZMh\m:{IHnubIljcXSrb36gc4YhW0GUUz3Dc3YuOiCrbnT1Z4VlKGO7dH;0c5hq[2m2eTDv[kBXTVKRLVW2JINmdGy|IHHmeIVzKDR6IHjveZJ{KCCneIDvd5Vz\SC2bzCwMlAyKE2RSTDTRXJUKEOxVj2yJJZqenW|IHL5JIhq\2hiY3;ueIVvfCCrbXHnbY5oNCCLQ{WwQVE1NjZ2zszNMi=> NHm5fGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTh5NUKvK|5EcEWPQly8M4E,
In vivo RAF265 shows 71% to 72% TVI% (tumor volume inhibition percentage) in HCT116 xenografts at 12 mg/kg. While the combination of RAF265 and RAD001 shows enhanced antitumor activity with increased T10 (time to achieve a relative tumor volume of 10 times the initial tumor volume) and tumor growth delay. The combination of RAD001 and RAF265 also significantly enhances the activation of caspase-3 in HCT116 and MDAMB231 but not in A549 xenografts. [2] RAF265 inhibits FDG (2-deoxy-2-[18F]fluoro-d-glucose) accumulation and decreases the tumor volumes in A375M xenografts by orally dosed of 100 mg/kg. [5]

Protocol (from reference)

Kinase Assay:[1]
  • Assay Protocol:

    Raf and Mek are combined at 2 × final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2. 0.1 mM EDTA and 1 mM DTT) and dispensed 15 μL per well in polypropylene assay plates. Background levels are determined in wells containing Mek and DMSO without Raf. To the Raf/Mek containing wells is added 3 μL of 10 × of RAF265 diluted in 100% DMSO. The raf kinase activity reaction is started by the addition of 12 μL per well of 2.5 × 33P-ATP diluted in assay buffer. After 45-60 minutes, the reactions are stopped with the addition of 70 μL of stop reagent (30 mM EDTA). Filtration plates are pre-wetted for 5 min with 70% ethanol, and then rinsed by filtration with wash buffer. Samples (90 μL) from the reaction wells are then transferred to the filtration plates. The filtration plates are washed 6 × with wash buffer using Millipore filtration apparatus. The plates are dried and 100 μL per well of scintillation fluid is added. The CPM is then determined using a Wallac Microbeta 1450 reader.

Cell Research:[2]
  • Cell lines: Human A549 and H460 lung, HT29 and HCT 116 colon, and MDAMB231 breast cancer cell lines
  • Concentrations: 0.1 - 10 μM
  • Incubation Time: 48 hours
  • Method: The MTT assay and Bliss additivism model are used to assess the effect of RAF265 on cell viability. In each well of a 96-well plate, 1 × 104 cells are grown in 200 μL of medium. After 24 hours, RAF265 is added to achieve a final concentration of 0.1 to 10 μM. After 48 hours of treatment, 20 μL of 5 mg/mL MTT solution in PBS is added to each well. After 4 hours, supernatant is removed and formazan crystals are discarded in 200 μL of DMSO. Absorbance is then measured at 595 nm using an absorbance plate reader. Data are expressed as the percentage of viable cells.
Animal Research:[2]
  • Animal Models: A549, H460, HCT116, or MDAMB231 cells are injected s.c. into the flank region of 6-wk-old female athymic mice.
  • Dosages: 12 mg/kg
  • Administration: Orally administered daily

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 518.41
Formula

C24H16F6N6O

CAS No. 927880-90-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01352273 Completed Drug: MEK162 + RAF265 Advanced Solid Tumors Array Biopharma now a wholly owned subsidiary of Pfizer|Array BioPharma June 2011 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy RAF265 (CHIR-265) | RAF265 (CHIR-265) supplier | purchase RAF265 (CHIR-265) | RAF265 (CHIR-265) cost | RAF265 (CHIR-265) manufacturer | order RAF265 (CHIR-265) | RAF265 (CHIR-265) distributor